Modality
Vaccine
MOA
BETi
Target
PSMA
Pathway
Incretin
CeliacDLBCL
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
Mar 2017
→ Jan 2031
Phase 2Current
NCT03122159
2,420 pts·Celiac
2017-03→2025-08·Active
NCT05276394
2,358 pts·DLBCL
2024-02→2031-01·Completed
4,778 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-217mo agoPh2 Data· Celiac
2031-01-014.8y awayPh2 Data· DLBCL
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Active
P2
Complet…
Catalysts
Ph2 Data
2025-08-21 · 7mo ago
Celiac
Ph2 Data
2031-01-01 · 4.8y away
DLBCL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03122159 | Phase 2 | Celiac | Active | 2420 | UPDRS |
| NCT05276394 | Phase 2 | DLBCL | Completed | 2358 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| BGN-3859 | BeiGene | Approved | PSMA |